Meta AnalysisID 7309
培门冬酶在儿童急性淋巴细胞白血病中的毒性：系统评价与单中心经验
CRD42023409202
We propose a systematic review with meta-analysis on the toxicity of peg asparaginase in pediatric patients with acute lymphoblastic leukemia. Numerous studies have dealt with this topic, so we find it interesting to sum
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 7309
- Evidence Id
- 15867
- Core Evidence Id
- 15867
- Source Meta Analysis Id
- 7297
- Herb2 Meta Analysis Id
- HBMA007297
- Crd Id
- CRD42023409202
- Title
- Peg-asparaginase toxicity in pediatric patients with acute lymphoblastic leukemia: systematic review with monocentric experience
- Review Question
- We propose a systematic review with meta-analysis on the toxicity of peg asparaginase in pediatric patients with acute lymphoblastic leukemia. Numerous studies have dealt with this topic, so we find it interesting to summarize the data obtained.
- Study Type Included
- Randomized controlled trials (RCTs), non-randomized controlled trials, prospective, or retrospective cohort studies
- Condition Being Studied
- Acute lymphoblastic leukemia (ALL) is the most common malignancy diagnosed in children, representing more than a quarter of all pediatric cancers. Acute lymphoblastic leukemia affects the immature forms of white blood cells, called lymphocytes. Pegaspargase, a pegylated form of native Escherichia coli-derived L-asparaginase, is indicated in the USA and EU for the treatment of acute lymphoblastic leukaemia (ALL) as a component of multi-agent chemotherapy in paediatric and adult patients. Numerous studies have dealt with the toxicity of peg asparaginase, we propose a systematic review on the subject.
- Participant
- patients under 18 years of age, diagnosed with acute lymphoblastic leukemia, treated with peg asparaginase
- Animal
- Human Disease Modelled
- Intervention
- All patients observed by us must have undergone treatment with peg asparaginase, during the treatment of acute lymphoblastic leukemia, with or without the development of toxic side-effects.
- Comparator Control
- Pediatric patients with acute lymphoblastic leukemia treated or untreated with peg asparaginase
- Main Outcome
- To compare the toxic effects of peg asparaginase therapy in pediatric patients with leukemia, analyzing the methods and therapeutic doses used. It could be interesting to dwell on any prophylactic therapies to peg asparaginase or on the supportive therapies necessary for the management of adverse events. We would also like to compare the data obtained from the meta-analysis with data from our direct experience at the University of Campania L. Vanvitelli.
- Outcome Measure
- Additional Outcome
- Study Method
- Meta-analysis, Prevention, Prognostic, Systematic review
- Keyword
- Asparaginase; Child; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Contact
- Maria Maddalena Marrapodi [email protected]
- Organisational Affiliation
- Università della Campania L. Vanvitelli
- Funding Source
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- Italy
- Review Stage
- Review Ongoing
- First Submission Date
- 2023-03-20
- Registration Date
- 2023-03-31
- Anticipated Start Date
- 2023-03-12
- Anticipated Completion Date
- 2024-04-30
- Title Cn
- 培门冬酶在儿童急性淋巴细胞白血病中的毒性：系统评价与单中心经验
- Title En
- Peg-asparaginase toxicity in pediatric patients with acute lymphoblastic leukemia: systematic review with monocentric experience
- Bilingual Status
- complete